Knights of Columbus Asset Advisors’s Coherus Oncology CHRS Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,922	Closed	-$53.5K	–	403
2024 Q2	$53.5K	Hold	30,922	–	–	﹤0.01%	373
2024 Q1	$73.9K	Sell	30,922 -30,922	-50%	-$76.1K	0.01%	348
2023 Q4	$206K	Buy	61,844 +30,922	+100%	+$82.8K	0.01%	313
2023 Q3	$116K	Buy	+30,922	New	+$143K	0.01%	339
2021 Q1	–	Sell	-145,647	Closed	-$2.53M	–	326
2020 Q4	$2.53M	Sell	145,647 -19	-0%	-$338	0.27%	131
2020 Q3	$2.67M	Buy	145,666 +6,941	+5%	+$129K	0.33%	104
2020 Q2	$2.48M	Buy	138,725 +440	+0.3%	+$7.45K	0.3%	108
2020 Q1	$2.24M	Buy	138,285 +70,089	+103%	+$1.29M	0.28%	109
2019 Q4	$1.23M	Buy	+68,196	New	+$1.26M	0.11%	302

Other funds holding CHRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Knights of Columbus Asset Advisors's CHRS Position: Q3 2024 in Review

Knights of Columbus Asset Advisors sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 30,922 shares — an estimated $53.5K sold.

Knights of Columbus Asset Advisors first reported a position in CHRS in Q4 2019 and held it in 9 quarters. The position peaked at $2.67M in Q3 2020. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

Knights of Columbus Asset Advisors reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 30,922 Coherus Oncology shares in Q3 2024, an estimated $53.5K.
Knights of Columbus Asset Advisors first reported a position in Coherus Oncology in Q4 2019 and held it in 9 quarters.
Knights of Columbus Asset Advisors's Coherus Oncology position peaked at $2.67M in Q3 2020.
128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Knights of Columbus Asset Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.